TTrialPathMatch Me to Trials
← Back to trials
RecruitingLocally Advanced Urothelial CarcinomaOligo-metastaic Urothelial Carcinoma

Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma

Eligible age

18+ yrs

Accepts

All genders

Locations

2 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study investigates the therapeutic benefit of consolidative local therapy with extirpative surgery for participants with locally advanced or oligo-metastatic urothelial carcinoma that have disease control with enfortumab vedotin-based systemic therapy and surgically resectable or previously radiated metastatic sites.

Sponsor: Yale University

You may qualify if…

  • ✓ 1. Be at least 18 years of age.
  • ✓ 2. Have provided informed consent.
  • ✓ 3. Have ECOG Performance status of 0 or 1.
  • ✓ 4. Be surgical candidate for extirpative surgery of primary site with standard bilateral pelvic lymph node dissection and urinary diversion at the discretion of urological oncologist.
  • ✓ 5. If applicable, must be a surgical candidate for resection of non-irradiated metastatic lesion(s) at the discretion of the treating surgeon.
  • ✓ 6. Have adequate organ function as defined by:
  • ✓ 1. Hgb \>9.0 ng/dL.
  • ✓ 2. WBC \>3.0 K/mcL.

You may not qualify if…

  • ✕ Participants who meet any of the following criteria will be excluded from study entry.
  • ✕ 1. Received systemic anti-cancer therapy within three weeks prior to the surgery.
  • ✕ 2. Received radiotherapy within two weeks prior to the surgery.
  • ✕ 3. Have a positive serum pregnancy test or women who are breastfeeding.
  • ✕ 4. Have other concurrent medical, surgical or psychiatric conditions that, in the treating investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
  • ✕ 5. Have any medical condition that, in the treating investigator's opinion, poses an undue risk to the participant's participation in the study.
  • ✕ 6. Have history of central nervous system (CNS) metastasis and/or leptomeningeal metastasis.

Where it's recruiting

Connecticut

New Haven

Wisconsin

Madison

Source: ClinicalTrials.gov · NCT07048457 · last updated 2026-10-07

Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carci · TrialPath